TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Managed Healthcare Executive6d
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
US FDA approves injectable version of Roche's multiple sclerosis therapy
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...
Drug Store News2d
FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology
Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...
Multiple Sclerosis News Today6d
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Pharmabiz5d
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
Daily3d
Roche gets USFDA nod for Ocrevus Zunovo for relapsing and progressive multiple sclerosis
Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...
Medscape8d
FDA Okays Subcutaneous Ocrelizumab for MS
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
Monthly Prescribing Reference9d
SC-Administration Ocrevus Zunovo Approved for Multiple Sclerosis
Treatment with the SC formulation was also found to be consistent with IV administration with regard to suppression of relapse activity and MRI lesions. The most common adverse reactions reported with ...